Abstract:Strongyloidiasis is a neglected tropical disease estimated to affect more than 600 million people worldwide. Recently, the World Health Organization road map on neglected tropical diseases 2021–2030 has put the focus on strongyloidiasis, including this disease within its mass drug administration campaigns. With the use of ivermectin in extensive treatment of all populations at-risk, identifying effective therapeutic alternatives is crucial in case ivermectin resistance arises. The objective of the present study was the development of a larval migration inhibition assay to evaluate the anthelmintic efficacy of commercial drugs and diamine and aminoalcohol derivatives against infective Strongyloides ratti third stage larvae. Through this technique, we successfully screened and estimated the in vitro anthelmintic efficacy of six commercial drugs, seven diamine derivatives and eight aminoalcohol derivatives. Unexpectedly, the half-maximal effective concentration of ivermectin and moxidectin (2.21 and 2.34 μM, respectively) were observed as the highest value obtained among all commercial drugs tested by this in vitro technique. Moreover, some diamine and aminoalcohol derivatives showed superior efficacy inhibiting S . ratti motility compared to ivermectin, with five compounds (AA23, AA34, AO2 AO7 and AO14b) also displaying selectivity indexes on HepG2 and Caco2 higher than 1. These findings underscore the potential of these derivatives as promising alternatives for strongyloidiasis treatment, warranting further investigation and in vivo efficacy assessment. Strongyloidiasis, a parasitic infection affecting over 600 million people worldwide, is increasingly recognized in global health initiatives. Caused by the nematode Strongyloides stercoralis , it predominantly occurs in tropical and subtropical regions. Transmission results through contact with soil contaminated by infectious larvae, leading to a spectrum of clinical symptoms from mild gastrointestinal discomfort to potentially life-threatening complications, especially in individuals with weakened immune systems. Despite its designation as a neglected tropical disease, concerns regarding the development of drug resistance highlight the need to explore alternative treatment strategies. In our study, we employed innovative methods to evaluate the in vitro efficacy of various drug candidates against Strongyloides ratti larvae, representing a crucial step in identifying novel therapies for human strongyloidiasis. Our findings revealed that some of the novel compounds tested, showed superior efficacy in inhibiting parasite motility, suggesting potential benefits for patient treatment outcomes. Our study underscores the urgent need for diversified treatment approaches in combating strongyloidiasis.

A new primary screening test for anthelmintics utilizing the parasitic stages of Nippostrongylus brasiliensis, in vitro

Three Small Molecule Entities (MPK18, MPK334 and YAK308) with Activity against Haemonchus contortus In Vitro

An Extensive Comparison of the Effect of Anthelmintic Classes on Diverse Nematodes

In Vivo and in Vitro Studies of Cry5B and Nicotinic Acetylcholine Receptor Agonist Anthelmintics Reveal a Powerful and Unique Combination Therapy Against Intestinal Nematode Parasites

High-Throughput Phenotypic Assay to Screen for Anthelmintic Activity on Haemonchus contortus

High-throughput screening of more than 30,000 compounds for anthelmintics against gastrointestinal nematode parasites

Two in vitro methods for screening potential parasiticides against Ichthyophthirius multifiliis using Tetrahymena thermophila.

Screening of a drug repurposing library with a nematode motility assay identifies promising anthelmintic hits against Cooperia oncophora and other ruminant parasites

Discovery of a Highly Synergistic Anthelmintic Combination That Shows Mutual Hypersusceptibility

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity

In Vitro and In Silico Anthelmintic Activity of Extracts of Lannea kerstingii and Ficus thonningii on Heligmosomoides polygyrus

Natural Compounds from the Marine Brown Alga Caulocystis cephalornithos with Potent In Vitro-Activity against the Parasitic Nematode Haemonchus contortus

High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni

Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test

Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis

High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites

A phenotypic screen of the Global Health Priority Box identifies an insecticide with anthelmintic activity

Assay Strategies for the Discovery and Validation of Therapeutics Targeting Brugia Pahangi Hsp90

The ATP bioluminescence assay: a new application and optimization for viability testing in the parasitic nematode Haemonchus contortus

Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity

Larval motility assay using WMicrotracker™: a high throughput test to discriminate between resistance and susceptibility to anthelmintic drugs in nematodes